Movement Alert｜CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery

Market Focus07-20

On July 20, CSPC Pharmaceutical Group rose 3.21% in regular trading, trading at HKD 8.47 per share, with turnover of HKD 129 million. The move was driven by the company's first ADC new drug application being accepted by China's NMPA, combined with a broad pharmaceutical sector recovery.

On July 17, CSPC announced that its envertamab injection, a HER2-targeting antibody-drug conjugate (ADC) classified as a Category 1 biologic, had its new drug application accepted by the NMPA. The drug targets unresectable or metastatic HER2-positive adult breast cancer patients who have received prior anti-HER2 therapy. A pivotal Phase III trial demonstrated significantly improved progression-free survival compared to T-DM1, with favorable safety.

The stock also benefited from a string of recent catalysts, including breakthrough therapy designation for its albumin-bound docetaxel and anbenitamab combination in first-line HER2-positive breast cancer, and receipt of a USD 25 million development milestone payment from AstraZeneca. The broader pharmaceutical sector showed strength, with Hansoh Pharma up 2.64%, Hengrui Pharma up 2.91%, and Asymchem up 4.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172918626?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172918626","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery","media":"Market Focus","content":"<p><p>On July 20, CSPC Pharmaceutical Group rose 3.21% in regular trading, trading at HKD 8.47 per share, with turnover of HKD 129 million. The move was driven by the company's first ADC new drug application being accepted by China's NMPA, combined with a broad pharmaceutical sector recovery.</p><p>On July 17, CSPC announced that its envertamab injection, a HER2-targeting antibody-drug conjugate (ADC) classified as a Category 1 biologic, had its new drug application accepted by the NMPA. The drug targets unresectable or metastatic HER2-positive adult breast cancer patients who have received prior anti-HER2 therapy. A pivotal Phase III trial demonstrated significantly improved progression-free survival compared to T-DM1, with favorable safety.</p><p>The stock also benefited from a string of recent catalysts, including breakthrough therapy designation for its albumin-bound docetaxel and anbenitamab combination in first-line HER2-positive breast cancer, and receipt of a USD 25 million development milestone payment from AstraZeneca. The broader pharmaceutical sector showed strength, with Hansoh Pharma up 2.64%, Hengrui Pharma up 2.91%, and Asymchem up 4.01%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Rises 3.21% in Regular Trading, First ADC Drug Application Accepted Amid Sector Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 09:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, CSPC Pharmaceutical Group rose 3.21% in regular trading, trading at HKD 8.47 per share, with turnover of HKD 129 million. The move was driven by the company's first ADC new drug application being accepted by China's NMPA, combined with a broad pharmaceutical sector recovery.</p><p>On July 17, CSPC announced that its envertamab injection, a HER2-targeting antibody-drug conjugate (ADC) classified as a Category 1 biologic, had its new drug application accepted by the NMPA. The drug targets unresectable or metastatic HER2-positive adult breast cancer patients who have received prior anti-HER2 therapy. A pivotal Phase III trial demonstrated significantly improved progression-free survival compared to T-DM1, with favorable safety.</p><p>The stock also benefited from a string of recent catalysts, including breakthrough therapy designation for its albumin-bound docetaxel and anbenitamab combination in first-line HER2-positive breast cancer, and receipt of a USD 25 million development milestone payment from AstraZeneca. The broader pharmaceutical sector showed strength, with Hansoh Pharma up 2.64%, Hengrui Pharma up 2.91%, and Asymchem up 4.01%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1172918626","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172918626","pubTimestamp":1784512486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, CSPC Pharmaceutical Group rose 3.21% in regular trading, trading at HKD 8.47 per share, with turnover of HKD 129 million. The move was driven by the company's first ADC new drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势提醒|石药集团常规交易上涨3.21%，首个ADC药物申请在板块复苏中受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On July 20, CSPC Pharmaceutical Group rose 3.21% in regular trading, trading at HKD 8.47 per share, with turnover of HKD 129 million. The move was driven by the company's first ADC new drug application being accepted by China's NMPA, combined with a broad pharmaceutical sector recovery.On July 17, CSPC announced that its envertamab injection, a HER2-targeting antibody-drug conjugate (ADC) classified as a Category 1 biologic, had its new drug application accepted by the NMPA. The drug targets unresectable or metastatic HER2-positive adult breast cancer patients who have received prior anti-HER2 therapy. A pivotal Phase III trial demonstrated significantly improved progression-free survival compared to T-DM1, with favorable safety.The stock also benefited from a string of recent catalysts, including breakthrough therapy designation for its albumin-bound docetaxel and anbenitamab combination in first-line HER2-positive breast cancer, and receipt of a USD 25 million development milestone payment from AstraZeneca. The broader pharmaceutical sector showed strength, with Hansoh Pharma up 2.64%, Hengrui Pharma up 2.91%, and Asymchem up 4.01%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172918626","isCrawlerRequest":true}